Is RNASEL :p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?

Background Breast cancer risk for BRCA1 and BRCA2 pathogenic mutation carriers is modified by risk factors that cluster in families, including genetic modifiers of risk. We considered genetic modifiers of risk for carriers of high-risk mutations in other breast cancer susceptibility genes. Methods In a family known to carry the high-risk mutation PALB2 :c.3113G>A (p.Trp1038*), whole-exome sequencing was performed on germline DNA from four affected women, three of whom were mutation carriers. Results RNASEL: p.Glu265* was identified in one of the PALB2 carriers who had two primary invasive breast cancer diagnoses before 50 years. Gene-panel testing of BRCA1 , BRCA2, PALB2 and RNASEL in the Australian Breast Cancer Family Registry identified five carriers of RNASEL: p.Glu265* in 591 early onset breast cancer cases. Three of the five women (60%) carrying RNASEL :p.Glu265* also carried a pathogenic mutation in a breast cancer susceptibility gene compared with 30 carriers of pathogenic mutations in the 586 non-carriers of RNASEL :p.Glu265* (5%) ( p < 0.002). Taqman genotyping demonstrated that the allele frequency of RNASEL :p.Glu265* was similar in affected and unaffected Australian women, consistent with other populations. Conclusion Our study suggests that RNASEL: p.Glu265* may be a genetic modifier of risk for early-onset breast cancer predisposition in carriers of high-risk mutations. Much larger case-case and case-control studies are warranted to test the association observed in this report.